EDIT vs NTLA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. EDIT and NTLA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined EDIT and NTLA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Editas Medicine (EDIT) is a clinical-stage biotechnology company developing gene-editing medicines based on CRISPR technology. It aims to treat serious diseases by making precise changes to DNA, and has shifted its strategy toward in vivo genomic medicines, which edit genes directly inside the body, after earlier work on ex vivo cell therapies. Its lead program, EDIT-401, is an experimental in vivo therapy aimed at lowering cholesterol-related risk. On October 8, 2026 Editas received approval in Australia to begin Strive, a Phase 1/2 first-in-human trial in patients with heterozygous familial hypercholesterolemia, with dosing expected to begin in 2026 and initial safety data in the first quarter of 2027. Editas is unprofitable and pre-commercial: it has no approved products and generates only modest revenue, mostly from licensing its intellectual property, while spending heavily on research and burning cash each quarter. Cash stood at roughly $124 million at the end of March 2026, when the company projected a runway into the third quarter of 2027, and had risen to ~$212 million by June 30, 2026, per Yahoo Finance data, alongside workforce reductions (to about 87 employees) meant to focus spending on its lead programs. Trailing twelve-month revenue is ~$47 million and the trailing net loss ~$74 million. As of October 16, 2026 the stock closed near $2.40, up ~17% year to date and down ~39% over one year, and the next quarterly report is expected around November 9. Headquartered in Cambridge, Massachusetts, Editas is a highly speculative, science-stage company whose value depends almost entirely on unproven clinical results, financing, and the broader competition to turn CRISPR editing into approved therapies. Nothing here is investment advice.

Full EDIT guide

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, developing genome-editing therapies based on CRISPR/Cas9. Its core differentiator is a proprietary in vivo platform that delivers the editing machinery directly into the body, typically the liver, using lipid nanoparticles, so that a single dose can permanently inactivate or modify a disease-causing gene without removing cells from the patient. This contrasts with ex vivo approaches that edit cells outside the body and reinfuse them. The company is pre-revenue from products and currently records only collaboration revenue from partners; it funds operations through its cash reserves and periodic capital raises.

Full NTLA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• EDIT drivers: CRISPR gene-editing platform; Focus on in vivo medicines and EDIT-401.
• NTLA drivers: Positive Late-Stage Lonvo-z Data in Hereditary Angioedema; In Vivo CRISPR Platform.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Editas is a highly speculative, clinical-stage biotech with no approved products and no meaningful product revenue, and it loses money and burns cash every quarter. For NTLA, intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick EDIT if you believe its drivers more; NTLA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the EDIT and NTLA guides.

EDIT. Editas cannot be valued on normal earnings measures because it is pre-commercial and unprofitable, so metrics like P/E do not apply. At ~$369 million, its market value sits not far above its ~$212 million of mid-2026 cash, so the market is assigning modest value to the pipeline and CRISPR intellectual property ahead of the first human EDIT-401 data in early 2027. Cash runway matters because an unprofitable biotech that runs low on cash typically must raise money by issuing new shares, which dilutes existing holders. All figures are approximate, are drawn from a fast-changing clinical-stage company, and can change quickly; verify current numbers before relying on them.

NTLA. Because Intellia has no product profits and only collaboration revenue, earnings-based multiples like P/E are negative and not analytically useful; at about $1.57 billion the market value sits at roughly 2 times book. The stock is better evaluated on its cash runway relative to a trailing operating cash outflow of about $347 million, the probability and timing of approval for lonvo-z (FDA decision due March 10, 2027) and nex-z, and the risk-adjusted commercial potential of those programs. The April 2026 equity raise and the September 2026 OrbiMed debt facility extend the runway, but pre-profit biotechs of this type typically require additional capital before reaching sustained profitability, so dilution and the binary nature of regulatory and trial outcomes stay central to any valuation view.

Headline figures (approximate, October 2026): EDIT shows stage clinical-stage, pre-commercial (no approved products), profitability unprofitable; TTM net loss ~$74 million and ongoing cash burn, revenue (ttm) ~$47 million, mainly licensing and collaboration (Q2 2026 ~$11.9M), net loss (q2 2026) ~$18 million; EPS -$0.15 vs -$0.28 estimate; NTLA shows revenue (ttm to june 2026) ~$60M collaboration revenue; Q2 2026 ~$7.7M (-46% YoY), net loss (ttm) ~$400M; Q2 2026 ~$107M, eps (q2 2026 vs estimate) -$0.80 vs -$0.78, cash / debt ~$438M cash and short-term investments, ~$73M debt (June 2026).

EDIT and NTLA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined EDIT and NTLA exposure against your real portfolio. It is not an investment adviser.